Damora Therapeutics reported a $31.99 million net loss for Q3 2026.

Item 6.

Exhibits

73

Signatures

75 i

CAUTIONARY NOTE REGARDI NG FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "project," "continue," "potential," "ongoing," "goal," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding:

• our ability to successfully execute on our strategy for the discovery and development of DMR-001, DMR-002 and DMR-003;

• the success, cost and timing of our planned filing of investigational new drug applications or their equivalents, planned product development activities, and initiation of clinical trials of our current product candidates, including DMR-001, DMR-002, and DMR-003, and any future product candidates;

• our ability to retain the continued service of our directors, officers, key employees and consultants;

• our ability to continue to grow and manage our growth effectively;

• our ability to obtain regulatory approval for our current or future product candidates that we may identify or develop;

• our ability to ensure adequate supply of our current or future product candidates;

• our ability to maintain third-party relationships necessary to conduct our business;

• our ability to establish an adequate safety or efficacy profile for our current or future product candidates that we may pursue;

• the implementation and execution of our strategic plans for our business, our current or future product candidates we may develop and our technology;

• our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

• the rate and degree of market acceptance and clinical utility for our current or future product candidates we may develop;

• our estimates about the size of our market opportunity;

• our estimates of expenses, future revenues, capital requirements and our needs for additional financing;

• our ability to maintain and establish collaborations;

• our financial performance and liquidity;

• developments relating to our competitors and our industry, including the impact of government regulation;

• our ability to retain the continued service of our key professionals and consultants and to identify, hire and retain additional qualified professionals;

• our ability to maintain adequate internal controls over financial reporting;

• the effects of global economic uncertainty and financial market volatility caused by economic effects of volatility in inflation and interest rates, tariffs, geopolitical instability, changes in international trade relationships and conflicts; and

• other risks and uncertainties, including those listed under the section titled "Risk Factors.¹"

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual ii results to differ materially from current expectations include, among other things, the reasons described elsewhere in this Quarterly Report on Form 10-Q and those set forth in Part I, Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains estimates, projections, and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates, and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.

Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, "we," "us," "our," "Damora," and the "Company" refer to Damora Therapeutics, Inc. and, where appropriate, its consolidated subsidiaries.

Trademarks

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service marks, and trade na

Item 1. Finan cial Statements (Unaudited).

DAMORA THERAPEUTICS, INC.

Condensed Consolidated Ba lance Sheets (in thousands, except share and per share amounts)

September 30,

December 31,

2026

2025

Assets (unaudited)

Current assets

Cash and cash equivalents

$

349,656

$

257,624

Marketable securities

178,822

—

Prepaid expenses and other current assets

2,839

2,799

Total current assets

531,317

260,423

Operating lease right-of-use asset

830

68

Other assets, noncurrent

480

36

Total assets

$

532,627

$

260,527

Liabilities and shareholders' equity

Current liabilities

Accounts payable

$

6,084

$

444

Accrued expenses and other current liabilities

12,830

2,401

Paramora warrant obligation

11,862

—

Related party accounts payable and other current liabilities

4,963

17,221

Operating lease liabilities, current

153

—

Total current liabilities

35,892

20,066

Operating lease liabilities, noncurrent

946

53

Other liabilities, noncurrent

28

28

Total liabilities

36,866

20,147

Commitments and contingencies (Note 9)

Mezzanine equity

Preferred shares, par value of $ 0.00001 per share; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares and 159 shares issued and outstanding as of September 30, 2026 and December 31, 2025

—

1,341

Shareholders' equity

Series B non-voting convertible preferred shares, par value of $ 0.00001 per share;

16,366 shares authorized, issued and outstanding at September 30, 2026 and December 31, 2025

117,621

117,621

Series C non-voting convertible preferred shares, par value of $ 0.00001 per share;

43,882 shares authorized at September 30, 2026 and December 31, 2025; 1,722 and 43,882 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

12,376

297,291

Ordinary shares, par value of $ 0.00001 per share; 500,000,000 shares authorized at September 30, 2026 and 300,000,000 shares authorized at December 31, 2025;

1

—

Additional paid-in capital

944,307

310,688

Accumulated deficit

( 578,311

)

( 487,363

)

Accumulated other comprehensive (loss) income

( 233

)

802

Total shareholders' equity

495,761

239,039

Total liabilities and shareholders' equity

$

532,627

$

260,527

See accompanying notes to the unaudited interim condensed consolidated financial statements.

Damora Therapeutics, Inc.

Condensed Consolidated Statements of Oper ations and Comprehensive Loss (in thousands, except share and per share amounts)

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2026

2025

2026

2025

Operating expenses

Research and development

$

25,475

$

1,416

$

74,792

$

3,559

General and administrative

11,388

1,740

27,876

5,617

Total operating expenses

36,863

3,156

102,668

9,176

Loss from operations

( 36,863

)

( 3,156

)

( 102,668

)

( 9,176

)

Other income (expense), net

Gain on sale of IP

750

—

750

—

Interest income, net

4,159

42

11,288

166

Foreign exchange transaction loss, net

( 37

)

( 19

)

( 21

)

( 87

)

Total other income, net

4,872

23

12,017

79

Loss before income tax expense

( 31,991

)

( 3,133

)

( 90,651

)

( 9,097

)

Income tax expense

—

—

( 297

)

( 6

)

Net loss²

$²

( 31,991²

)

$

( 3,133

)

$

( 90,948

)

$

( 9,103

)

Net loss per share, basic and diluted, Series B Preferred Shares

$

( 400.40

)

$

—

$

( 1,188.20

)

$

—

Weighted-average Series B non-voting convertible preferred shares outstanding, basic and diluted

16,366

—

16,366

—

Net loss per share, basic and diluted, Series C Preferred Shares

$

( 400.40

)

$

—

$

( 1,188.20

)

$

—

Weighted-average Series C non-voting convertible preferred shares outstanding, basic and diluted

1,722

—

7,888

—

Net loss per share, basic and diluted, ordinary shares

$

( 0.40

)

$

( 2.36

)

$

( 1.19

)

$

( 6.88

)

Weighted-average number of shares used in computing net loss per ordinary share, basic and diluted

61,810,033

1,327,039

52,289,247

1,323,886

Other comprehensive (loss) income, net of tax

Currency translation gain (loss)

$

9

$

14

$

( 61

)

$

726

Unrealized loss on marketable securities, net of tax

( 974

)

-

( 974

)

-

Other comprehensive (loss) income, net of tax

( 965

)

14

( 1,035

)

726

Total comprehensive loss

$

( 32,956

)

$

( 3,119

)

$

( 91,983

)

$

( 8,377

)

See accompanying notes to the unaudited interim condensed consolidated financial statements.

2

Damora Therapeutics, Inc.

Condensed Consolidated Statemen ts of Changes in Shareholders' Equity (in thousands, except share amounts)

(Unaudited)

Mezzanine Equity

Shareholders' Equity

Three Months Ended September 30, 2025

Preferred Shares

Series B

Non-Voting

Convertible Preferred Shares

Series C

Non-Voting

Convertible Preferred Shares

Ordinary Shares

Additional

Paid-In

Accumulated

Accumulated

Other

Comprehensive

Total

Shareholders'

Shares

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

Income

Equity

Balance at June 30, 2025

159

$ 1,341

—

$—

—

$—

1,324,560

$—

292,297

$( 283,494 )

$ 809

$ 9,612

Stock-based compensation expense

—

—

—

—

—

—

—

—

164

—

—

164

Issuance of common stock in connection with vesting of restricted stock units

—

—

—

—

—

—

2,652

—

9

—

—

9

Other comprehensive income, net

—

—

—

—

—

—

—

—

—

14

14

Net loss

—

—

—

—

—

—

—

—

—

( 3,133 )

—

( 3,133 )

Balance at September 30, 2025

159

$ 1,341

—

$—

—

$—

1,327,212

$—

$ 292,470

$( 286,627 )

$ 823

$ 6,666

Mezzanine Equity

Shareholders' Equity

Three Months Ended September 30, 2026

Preferred Shares

Series B

Non-Voting

Convertible Preferred Shares

Series C

Non-Voting

Convertible Preferred Shares

Ordinary Shares

Additional

Paid-In

Accumulated

Accumulated

Other

Comprehensive

Total

Shareholders'

Shares

Amount

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Deficit

Income (Loss)

Equity

Balance at June 30, 2026

—

$-

16,366

$ 117,621

1,722

$ 12,376

61,734,601

$ 1

$ 931,649

$( 546,320 )

$ 732

$ 516,059

Share-based compensation expense

—

—

—

—

—

—

—

—

7,541

—

—

7,541

Issuance of ordinary shares in connection with vesting of restricted share units

—

—

—

—

—

—

918

—

—

—

—

—

Exercise of options

—